Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 11, 2007, Pages 2987-2991

  Kulkarni, Santosh S ^a   Newman, Amy Hauck ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Metabotropic glutamate receptor 5; Non competitive antagonist; Suzuki Miyaura coupling

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 6 METHYL 2 AMINO PYRIDINE; 7 CHLORO 2 METHYL QUINOLINE; BENZAMIDE; BENZOTHIAZOLE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; NITROPYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANXIETY; ARTICLE; BINDING AFFINITY; DEPRESSION; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NEUROTRANSMISSION; PAIN; PHARMACOPHORE; RECEPTOR BLOCKING; SUBSTITUTION REACTION;

BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; HYDROLYSIS; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 34248176184     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.03.066     Document Type: Article

References (33)

1. Conn P.J., and Pin J.P. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 205
2. Spooren W.P.J.M., Gasparini F., Salt T.E., and Kuhn R. TIPS 22 (2001) 331
3. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., and Schoepp D.D. Nature Rev. Drug Discov. 4 (2005) 131
4. Brodkin J., Busse C., Sukoff S.J., and Varney M.A. Pharmacol. Biochem. Behav. 23 (2002) 207
5. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., and Pilc A. Br. J. Pharmacol. 132 (2001) 1423
6. Dolan S., Kelly J.G., Monteiro A.M., and Nolan A.M. Pain 106 (2003) 501
7. Yan Q.J., Rammal M., Tranfaglia M., and Bauchwitz R.P. Neuropharmacology 49 (2005) 1053
8. Li X., Need A.B., Baez M., and Witkin J.M. J. Pharmacol. Exp. Ther. 319 (2006) 254
9. Bear M.F. Genes Brain Behav. 4 (2005) 393
10. Chiamulera C., Eping-Jordon M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., Corsi M., Orzi F., and Conquet F. Nature Neurosci. 4 (2001) 873
11. Popik P., and Wrobel M. Neuropharmacology 43 (2002) 1210
12. Paterson N.E., Semenova S., Gasparini F., and Markou A. Psychopharmacology (Berl.) 167 (2003) 257
13. Backstrom P., Bachteler D., Koch S., Hyytia P., and Spanagel R. Neuropsychopharmacology 29 (2004) 921
14. Gasparini F., Floersheim P., Flor P.J., Heinrich M., Inderbitzin W., Ott D., Pagano A., Stierlin C., Stoehr N., Vranesic I., and Kuhn R. Farmaco 56 (2001) 95
15. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., and Varney M.A. J. Med. Chem. 46 (2003) 204
16. Roppe J., Smith N.D., Huang D., Tehrani L., Wang B., Anderson J., Brodkin J., Chung J., Jiang X., King C., Munoz B., Varney M.A., Prasit P., and Cosford N.D. J. Med. Chem. 47 (2004) 4645
17. Wallberg A., Nilsson K., Osterlund K., Peterson A., Elg S., Raboisson P., Baur U., Hammerland L.G., and Mattsson J.P. Bioorg. Med. Chem. Lett. 16 (2006) 1142
18. Hammerland L.G., Johansson M., Malmstrom J., Mattsson J.P., Minidis A.B.E., Nilsson K., Peterson A., Wensbo D., Wallberg A., and Osterlund K. Bioorg. Med. Chem. Lett. 16 (2006) 2467
19. Buttelmann B., Peters J.U., Ceccarelli S., Kolczewski S., Vieira E., Prinssen E.P., Spooren W., Schuler F., Huwyler J., Porter R.H.P., and Jaeschke G. Bioorg. Med. Chem. Lett. 16 (2006) 1892
20. Kulkarni S.S., Nightangle B., Dersch C.M., Rothman R.B., and Newman A.H. Bioorg. Med. Chem. Lett. 16 (2006) 3371
21. Kulkarni S.S., and Newman A.H. Bioorg. Med. Chem. Lett. 17 (2007) 2074
22. Pagano A., Ruegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., Floersheim P., Prezeau L., Carroll F., Pin J.P., Cambria A., Vranesic I., Flor P.J., Gasparini F., and Kuhn R. J. Biol. Chem. 275 (2000) 33750
23. Malherbe P., Kratochwil N., Zenner M.T., Piussi J., Diener C., Kratzeisen C., Fischer C., and Porter R.H. Mol. Pharmacol. 64 (2003) 823
24. Barder T.E., Walker S.D., Martinelli J.R., and Buchwald S.L. J. Am. Chem. Soc. 127 (2005) 4685
25. Wolfe J.P., Singer R.A., Yang B.H., and Buchwald S.L. J. Am. Chem. Soc. 121 (1999) 9550
26. Ishiyama T., Murata M., and Miyaura N. J. Org. Chem. 60 (1995) 7508
27. Hutchinson I., Chua M.S., Browne H.L., Trapani V., Bradshaw T.D., Westwell A.D., and Stevens M.F.G. J. Med. Chem. 44 (2001) 1446
28. Parker E.D., and Shive W. J. Am. Chem. Soc. 69 (1947) 63
29. Molina P., Alajarin M., and Vidal A. Tetrahedron 45 (1989) 4263
30. 2O) C, H, N. The experimental and spectral data for all other compounds are reported in the Supporting information.
31. Binding affinities were determined by the National Institute on Mental Health-Psychoactive Drug Screening Program as described in http://pdsp.med.unc.edu/indexR.html.
32. Zhao Z., Wisnoski D.D., O'Brien J.A., Lemaire W., Williams D.L., Jacobson M.A., Wittman M., Ha S.N., Schaffhauser H., Sur C., Pettibone D.J., Duggan M.E., Conn P.J., Hartman G.D., and Lindsley C.W. Bioorg. Med. Chem. Lett. 17 (2006) 1386
33. Functional assay data were provided by the National Institute on Mental Health-Psychoactive Drug Screening Program (PDSP) using methods described in. Shi Q., Savage J.E., Hufeisen S.J., Rauser L., Grajkowska E., Ernsberger P., Wroblewski J.T., Nadeau J.H., and Roth B.L. J. Pharmacol. Exp. Ther. 305 (2003) 131